retatrutide success stories Semaglutide vs. Tirzepatide vs. My Retatrutide Journey: Week 4
Description
Akazawa Y, Okumura K, Ishii R, et al
Mounjaro introduced tirzepatide as a dual GIP/GLP-1 receptor agonist for type 2 diabetes
Future research should focus on mechanistic studies, long-term safety, and identifying biomarkers to predict dermatologic responses, ultimately guiding personalized treatment approaches
Screening recommendations include initial and subsequent dilated eye examinations by ophthalmologists or optometrists, with increased frequency if retinopathy is present or progressing
The best part was knowing I could reach out to my doctor whenever I needed
